ASH 2025 | A retrospective study of asciminib for R/R Ph+ ALL and LBC-CML

This is a retrospective study, derived indeed from the Campus ALL, which is a network working quite actively in Italy, in which we’ve been trying to collect patients with Philadelphia positive ALL who receive asciminib. Why asciminib? Because we know there is a different TKI inhibitor and we collected 19 patients, median age was 55 years, who were refractory or relapsed after several lines of treatment, including also immunotherapy. Of the 19 patients, the majority of them were, in fact, Philadelphia-positive ALL, a few cases were in the blast crisis of chronic myeloid leukemia and what we could show was that indeed we still do not know clearly which is the correct dosing of asciminib because different doses were tested and the majority of them were either 40 daily or 40 milligrams twice a day, even though there were some patients who also received higher doses of treatment. Indeed, just considering the population that was heavily pre-treated, we could show that overall survival at one year is 69%. So asciminib could work as possibly, according to the age of the patient and the feasibility of a subsequent stem cell transplant, to bridge these patients to transplantation. And indeed, it can be used in combination. The right combination is not yet clear. We don’t know exactly which is the best way to combine asciminib with other drugs, but for sure it can be effective also in this heavily pre-treated set of patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.